Chronic obstructive pulmonary disease in patients with coronary heart disease worsens long-term prognosis after percutaneous coronary interventions

Aim    To evaluate the incidence rate of major adverse cardiovascular events (MACVE) in the long-term following percutaneous coronary interventions (PCCI) in patients with acute and chronic ischemic heart disease (IHD) and the contribution of concurrent chronic obstructive pulmonary disease (COPD) to the long-term prediction.
Material and methods    This prospective cohort study included 254 patients with IHD and concurrent COPD and 392 patients with IHD without COPD. PCCI was performed in all patients: for acute coronary syndrome in 295 patients and for chronic IHD in 351 patients. The follow-up period lasted for up to 36 months. The outcome was a composite endpoint, MACVE, that included cardiovascular death, myocardial infarction, stroke, repeated unscheduled myocardial revascularization (MR), and the time to the event.
Results    The age-standardized incidence of MACVE in patients with IHD and COPD was 31.5 vs. 23.2 % in patients with IHD without concurrent COPD (p=0.025), primarily due to an increased frequency of repeated unscheduled MR (20.5 vs. 14.0 %, p=0.041), which was associated with earlier occurrence of adverse events (p<0.001). Repeated unscheduled MR was more frequently performed in patients with moderate COPD; the frequency of MR decreased with increasing severity of COPD, whereas the total incidence of cardiovascular death, myocardial infarction, and stroke was the highest in patients with severe and very severe COPD.
Conclusion    The presence of concurrent COPD increases the relative risk of MACVE 1.36 times (95 % confidence interval: 1.05–1.75) and facilitates their earlier development. Repeated unscheduled MR makes the major contribution to the increase in the total risk (relative risk, 1.46; 95 % confidence interval: 1.03–2.06). The increase in severity of COPD is associated with the increase in total frequency of MACVE (p=0.005).

1. Bundhun PK, Wu ZJ, Chen M-H. Coronary artery bypass surgery compared with percutaneous coronary interventions in patients with insulin-treated type 2 diabetes mellitus: a systematic review and metaanalysis of 6 randomized controlled trials. Cardiovascular Diabetology. 2016;15(1):2. DOI: 10.1186/s12933-015-0323-z

2. Koskinas KC, Siontis GCM, Piccolo R, Franzone A, Haynes A, RatWirtzler J et al. Impact of Diabetic Status on Outcomes After Revascularization with Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients. Circulation: Cardiovascular Interventions. 2016;9(2):e003255. DOI: 10.1161/CIRCINTERVENTIONS.115.003255

3. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN et al. Safety and Efficacy of Drug-Eluting Stents in Older Patients with Chronic Kidney Disease. Journal of the American College of Cardiology. 2011;58(18):1859–69. DOI: 10.1016/j.jacc.2011.06.056

4. Enriquez JR, Parikh SV, Selzer F, Jacobs AK, Marroquin O, Mulukutla S et al. Increased Adverse Events After Percutaneous Coronary Intervention in Patients With COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest. 2011;140(3):604–10. DOI: 10.1378/chest.10-2644

5. Andell P, Sjögren J, Batra G, Szummer K, Koul S. Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention. European Journal of Cardio-Thoracic Surgery. 2017;52(5):930–6. DOI: 10.1093/ejcts/ezx219

6. Șerban RC, Hadadi L, Șuș I, Lakatos EK, Demjen Z, Scridon A. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. International Journal of Cardiology. 2017; 243:437–42. DOI: 10.1016/j.ijcard.2017.05.044

7. Global Initiative for Chronic Obstructive Lung Disease 2021. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT2021-v1.1-25Nov20_WMV.pdf.

8. Averkov O.V., Duplyakov D.V., Gilyarov M.Yu., Novikova N.A., Shakhnovich R.M., Yakovlev A.N. et al. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):251–310. DOI: 10.15829/29/1560-4071-2020-4103

9. Jatene T, Biering-Sørensen T, Nochioka K, Mangione FM, Hansen KW, Sørensen R et al. Frequency of Cardiac Death and Stent Thrombosis in Patients with Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials). The American Journal of Cardiology. 2017;119(1):14–9. DOI: 10.1016/j.amjcard.2016.09.013

10. Zafiraki V.K., Kosmacheva E.D. Patient with coronary heart disease and chronic obstructive pulmonary disease in the era of endovascular interventions on coronary arteries. -M.-Krasnodar: Kuban State Medical University;2019. - 286 p. ISBN 978-5-903252-12-1

11. Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD. Journal of General Internal Medicine. 2018;33(9):1461–8. DOI: 10.1007/s11606-018-4518-3

12. Sand JMB, Leeming DJ, Byrjalsen I, Bihlet AR, Lange P, Tal-Singer R et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD – results from the ECLIPSE study. Respiratory Research. 2016;17(1):125. DOI: 10.1186/s12931-016-0440-6

13. Prokofievа T.V., Lipnitskаya E.A., Kuzmichev B.Yu., Poluninа O.S., Voroninа L.P., Poluninа E.A. The effect of chronic obstructive pulmonary disease on the level of homocysteinemia and the condition of coronary vessels in patients with myocardial infarction. Tuberculosis and Lung Diseases. 2019;97(10):12–8. DOI: 10.21292/2075-1230-2019-97-10-12-18

14. Maclay JD, McAllister DA, MacNee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007;12(5):634–41. DOI: 10.1111/j.1440-1843.2007.01136.x

15. Portillo K, Abad-Capa J, Ruiz-Manzano J. Enfermedad pulmonar obstructiva crónica y ventrículo izquierdo. Archivos de Bronconeumología. 2015;51(5):227–34. DOI: 10.1016/j.arbres.2014.03.012

16. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM. Systemic Effects of Smoking. Chest. 2007;131(5):1557–66. DOI: 10.1378/chest.06-2179

17. Yawn BP, Keenan JM. COPD—The Primary Care Perspective: Addressing Epidemiology, Pathology, Diagnosis, Treatment of Smoking’s Multiple Morbidities and the Patient’s Perspective. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2007;4(1):67–83. DOI: 10.1080/15412550601169562

18. Vanfleteren LEGW, Spruit MA, Groenen MTJ, Bruijnzeel PLB, Taib Z, Rutten EPA et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. European Respiratory Journal. 2014;43(5):1306–15. DOI: 10.1183/09031936.00169313

19. Man SFP, Van Eeden S, Sin DD. Vascular Risk in Chronic Obstructive Pulmonary Disease: Role of Inflammation and Other Mediators. Canadian Journal of Cardiology. 2012;28(6):653–61. DOI: 10.1016/j.cjca.2012.06.013

20. Rabinovich RA, MacNee W. Should we treat chronic obstructive pulmonary disease as a cardiovascular disease? Expert Review of Respiratory Medicine. 2015;9(4):459–72. DOI: 10.1586/17476348.2015.1070099

21. Wang R, Li J-Y, Cao Z, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2013;18(8):1244–8. DOI: 10.1111/resp.12143

22. Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2008;3(1):89–96. DOI: 10.2147/copd.s1401